Accessibility Menu
Kiora Pharmaceuticals logo

Kiora Pharmaceuticals(NASDAQ) KPRX

Market Cap$11.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-100%
1 Year-16%
1 Month-2%
$2.45
-2%
-0.05Today
Kiora Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 2.552026-07-24
Kiora Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.04%USD 2.632026-07-17
1 month-1.54%USD 2.592026-06-24
3 month+8.51%USD 2.352026-04-24
Year to date+29.44%USD 1.972025-12-31
1 year-16.39%USD 3.052025-07-24
3 year-52.88%USD 5.412023-07-25
5 year-99.79%USD 1,188.002021-07-23
Since inception-99.99%USD 30,510.032015-02-17

Kiora Pharmaceuticals Financials at a Glance

Market Cap

$11.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$11.06M

EPS (TTM)

-$2.85

P/E Ratio

-0.90

Dividend

$0.00

Beta (Volatility)

0.83 (Low)

Price

$2.45

Volume

1

Open

$2.50

Previous Close

$2.45

Daily Range

$2.29 - $2.55

52-Week Range

$1.76 - $3.06

Estimated Earnings Date

Aug 7, 2026

KPRX News

Foolcom-Featured.png

Kiora (KPRX) Q2 Revenue Falls 100%

Motley Fool Markets TeamAug 8, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kiora Pharmaceuticals

Kiora develops medicines for people with serious eye diseases. Its main products aim to restore vision or reduce eye inflammation. These treatments target patients with inherited blindness or eye problems from autoimmune diseases.

Products and Services

  • KIO-301 (Vision Restoration): A small molecule drug in clinical trials for inherited and age-related retinal diseases; no product revenue yet.
  • KIO-104 (Retinal Inflammation): An intravitreal drug in trials for diabetic eye swelling and non-infectious eye inflammation; no product revenue yet.
  • KIO-101 (Autoimmune Eye Disease): An eye drop for eye symptoms of autoimmune diseases, available for partnership; no product revenue yet.
  • Discontinued KIO-201: Previously developed for corneal wound repair after eye surgery; development stopped in July 2024.

Growth and Expansion

  • Signed global co-development deal with Thea Open Innovation in 2024 for KIO-301, with $16 million upfront and up to $285 million in milestones.
  • Entered exclusive option agreement with Senju Pharmaceutical in 2025 for KIO-301 rights in Asia, receiving $1.25 million upfront.
  • Expanded clinical trial sites to Australia and New Zealand in 2025 to support KIO-301 Phase 2 studies.
  • Ceased development of KIO-201 in July 2024 to focus resources on core pipeline.

What Makes Kiora Stand Out

Kiora uses a unique approach to vision restoration, focusing on small molecule drugs instead of gene therapy. Its main product, KIO-301, has special regulatory status for rare eye diseases, which can offer market exclusivity. The company relies on global partners for funding and commercialization, reducing its direct financial risk.

Five Things You Need to Know

  • Operating loss was $12.8 million in 2025, compared to $4.5 million income in 2024.
  • Cash and short-term investments totaled $17.1 million as of December 31, 2025.
  • R&D expenses rose to $10.8 million in 2025, up 37.5% from 2024.
  • Full-time employees numbered 13 at the end of 2025.

Bottom Line

Kiora has shifted from early-stage research to clinical development, focusing on rare eye diseases. Its future depends on clinical trial results and continued support from global partners.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

13

CEO

Brian Matthew Strem, PhD

Website

www.kiorapharma.com

Headquarters

Encinitas, CA 92024, US

KPRX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-59.30%

Return on Capital

-57.35%

Return on Assets

-52.10%

Earnings Yield

-1.11%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.43M

Volume

1

Avg. Volume

39.67K

Financials (TTM)

Gross Profit

-$41.98K

Operating Income

-$13.00M

EBITDA

-$12.39M

Operating Cash Flow

-$10.42M

Capital Expenditure

-$115.81K

Free Cash Flow

-$10.53M

Cash & ST Invst.

$13.87M

Total Debt

$373.59K

Kiora Pharmaceuticals Performance Analysis

Kiora Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 16,020,000N/A
20252025-12-31USD 0N/A
Kiora Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Kiora Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -166.94-67.5%
20232023-12-31USD -24.25-85.5%
20242024-12-31USD 0.87N/A
20252025-12-31USD -2.60N/A
Kiora Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-3.8%
Q32025-09-30101.1%
Q42025-12-31-25745.2%
Q12026-03-3163.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$41.98K

N/A

Gross Margin

0.00%

N/A

Market Cap

$11.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$869.34K

N/A

Employees

13

N/A

Net Income

-$2.42M

-10.3%

EBITDA

-$2.38M

-15.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$13.87M

-42.5%

Total Debt

$373.59K

+134.9%

Accounts Receivable

$3.45M

+67.5%

Inventory

$0.00

N/A

Long Term Debt

$195.37K

+123.4%

Short Term Debt

$178.22K

+149.1%

Return on Assets

-52.10%

N/A

Return on Invested Capital

-70.56%

N/A

Free Cash Flow

-$3.17M

-17.1%

Operating Cash Flow

-$3.16M

-16.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INABIN8bio, Inc.
$1.19-0.83%
PHIOPhio Pharmaceuticals Corp.
$1.05+0.96%
APVOAptevo Therapeutics Inc.
$4.21-4.10%
RNAZTransCode Therapeutics, Inc.
$5.80-2.19%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About KPRX

What is the current price of Kiora Pharmaceuticals?

Kiora Pharmaceuticals is trading at $2.45 per share.

What is the 52-week range for Kiora Pharmaceuticals?

Over the past 52 weeks, Kiora Pharmaceuticals has traded between $1.76 and $3.06.

How much debt does Kiora Pharmaceuticals have?

As of the most recent reporting period, Kiora Pharmaceuticals reported total debt of $373.59K.

How much cash does Kiora Pharmaceuticals have on hand?

Kiora Pharmaceuticals reported $10.96M in cash and cash equivalents in its most recent financial results.

What is Kiora Pharmaceuticals’s dividend yield?

Kiora Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services